Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection

被引:0
|
作者
Robert S. Rosenson
Wolfgang Koenig
机构
[1] Icahn School of Medicine at Mount Sinai,Cardiometabolics Unit, Mount Sinai Heart
[2] Technische Universität München,Klinik für Herz
来源
关键词
Mendelian randomization; Genetics; Atherosclerosis; Lipoproteins; Inflammation; Statins; PCSK9; Cholesterol ester transfer protein; Statins; Ezetimibe; Secretory phospholipase A2; Interleukin 6; Diabetes;
D O I
暂无
中图分类号
学科分类号
摘要
Genetic factors identified from genome-wide association studies have been used to understand causative variants for complex diseases. Studies conducted on large populations of individuals from many geographical regions have provided insights into genetic pathways involved in the causal pathway for atherosclerotic cardiovascular disease. A single genetic trait may ineffectively evaluate the pathway of interest, and it may not account for other complementary genetic pathways that may be activated at various stages of the disease process or evidence-based therapies that alter the molecular and cellular milieu.
引用
收藏
页码:65 / 74
页数:9
相关论文
共 50 条
  • [1] Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection
    Rosenson, Robert S.
    Koenig, Wolfgang
    CARDIOVASCULAR DRUGS AND THERAPY, 2016, 30 (01) : 65 - 74
  • [2] Limits of Mendelian Randomization Analyses in Selection of Secretory Phospholipase A2-IIA as a Valid Therapeutic Target for Prevention of Cardiovascular Disease
    Rosenson, Robert S.
    Hurt-Camejo, Eva
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (09) : 942 - 943
  • [3] Limits of Mendelian Randomization Analyses in Selection of Secretory Phospholipase A2-IIA as a Valid Therapeutic Target for Prevention of Cardiovascular Disease Reply
    Holmes, Michael V.
    Simon, Tabassome
    Exeter, Holly J.
    Hingorani, Aroon D.
    Sabatine, Marc S.
    Mallat, Ziad
    Casas, Juan P.
    Talmud, Philippa J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (09) : 943 - 943
  • [4] Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses
    Chen, Jie
    Xu, Fengzhe
    Ruan, Xixian
    Sun, Jing
    Zhang, Yao
    Zhang, Han
    Zhao, Jianhui
    Zheng, Jie
    Larsson, Susanna C.
    Wang, Xiaoyan
    Li, Xue
    Yuan, Shuai
    EBIOMEDICINE, 2023, 89
  • [5] Therapeutic Targets for Diabetic Kidney Disease: Proteome-Wide Mendelian Randomization and Colocalization Analyses
    Zhang, Wei
    Ma, Leilei
    Zhou, Qianyi
    Gu, Tianjiao
    Zhang, Xiaotian
    Xing, Haitao
    DIABETES, 2024, 73 (04) : 618 - 627
  • [6] Association of cardiovascular disease on cancer: observational and mendelian randomization analyses
    Bai, Tongtong
    Wu, Chengyu
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [7] Therapeutic targets for endometriosis: Genome-wide Mendelian randomization and colocalization analyses
    Zeng, Pengfei
    Lu, Liyue
    Zhang, Hanxiao
    Li, Yanting
    Tan, Shufa
    Yu, Tong
    Zhou, Hang
    GENE, 2024, 893
  • [8] Therapeutic targets for gastrointestinal diseases: proteome-wide Mendelian randomization and colocalization analyses
    Zhan, Daqin
    Yang, Zhihao
    Li, Pengcheng
    Pan, Jun
    POSTGRADUATE MEDICAL JOURNAL, 2024,
  • [9] Therapeutic targets for lung cancer: genome-wide Mendelian randomization and colocalization analyses
    Luan, Yi
    Xian, Desheng
    Zhao, Changwen
    Qing, Xin
    He, Hanlin
    Zheng, Kaixuan
    Song, Wenjun
    Jiang, Taijiao
    Wang, Wenjian
    Duan, Chaohui
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [10] Vitamin C and primary prevention of cardiovascular disease: the case for Mendelian randomization
    Santos, Raul D.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 28 (16) : 1838 - 1839